Personalized cancer vaccines from bacteria-derived outer membrane vesicles with antibody-mediated persistent uptake by dendritic cells

[1]  Yiye Li,et al.  Multifunctional biomolecule nanostructures for cancer therapy , 2021, Nature Reviews Materials.

[2]  Jie Liang,et al.  Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology , 2021, Nature Communications.

[3]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[4]  F. André,et al.  Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies. , 2021, Cancer discovery.

[5]  Brian J. Stevenson,et al.  Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer , 2021, npj Vaccines.

[6]  Michelle S. Miller,et al.  Targeting a neoantigen derived from a common TP53 mutation , 2021, Science.

[7]  R. Reiter,et al.  High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors , 2020, Clinical Cancer Research.

[8]  Shuang Wang,et al.  Biomineralized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy , 2020, Advanced materials.

[9]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[10]  Yuki Saito,et al.  Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer , 2020, Cancer science.

[11]  R. Jain,et al.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges , 2020, Nature Reviews Clinical Oncology.

[12]  Russ B. Altman,et al.  Predicting HLA class II antigen presentation through integrated deep learning , 2019, Nature Biotechnology.

[13]  Daniel G. Anderson,et al.  Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation , 2019, Nature Biotechnology.

[14]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[15]  Jia Wei,et al.  Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. , 2019, The Journal of clinical investigation.

[16]  Diana Tichy,et al.  Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC–Peptide Binding Data Set , 2019, Cancer Immunology Research.

[17]  Xiaoyuan Chen,et al.  Vesicular Antibodies: A Bioactive Multifunctional Combination Platform for Targeted Therapeutic Delivery and Cancer Immunotherapy , 2019, Advanced materials.

[18]  R. Hollingsworth,et al.  Turning the corner on therapeutic cancer vaccines , 2019, npj Vaccines.

[19]  F. Kiessling,et al.  Nanomedicine and macroscale materials in immuno-oncology. , 2019, Chemical Society reviews.

[20]  Yury B. Porozov,et al.  TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis , 2017, Vaccines.

[21]  D. Martens,et al.  Bioengineering bacterial outer membrane vesicles as vaccine platform. , 2017, Biotechnology advances.

[22]  Yongzhuo Huang,et al.  Microneedle-Assisted, DC-Targeted Codelivery of pTRP-2 and Adjuvant of Paclitaxel for Transcutaneous Immunotherapy. , 2017, Small.

[23]  Zhijian J. Chen,et al.  A STING-Activating Nanovaccine for Cancer Immunotherapy , 2017, Nature nanotechnology.

[24]  D. White,et al.  CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. , 2017, Blood.

[25]  R. DePinho,et al.  Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer , 2017, Nature.

[26]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[27]  Ton N. Schumacher,et al.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.

[28]  M. Kuehn,et al.  Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions , 2015, Nature Reviews Microbiology.

[29]  I. Mellman,et al.  Neo approaches to cancer vaccines , 2015, Science.

[30]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[31]  M. Kaparakis-Liaskos,et al.  Immune modulation by bacterial outer membrane vesicles , 2015, Nature Reviews Immunology.

[32]  A. Ciccodicola,et al.  Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response , 2015, EMBO molecular medicine.

[33]  G. Sinha.  Listeria vaccines join the checkpoint frenzy , 2014, Nature Biotechnology.

[34]  J. Yates,et al.  Ecto-Fc MS identifies ligand-receptor interactions through extracellular domain Fc fusion protein baits and shotgun proteomic analysis , 2014, Nature Protocols.

[35]  K. Tanizawa,et al.  Fluorophore-labeled nanocapsules displaying IgG Fc-binding domains for the simultaneous detection of multiple antigens. , 2011, Biomaterials.

[36]  B. Feng,et al.  3D antibody immobilization on a planar matrix surface. , 2011, Biosensors & bioelectronics.

[37]  D. Irvine,et al.  Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.

[38]  E. Choi,et al.  Nanocapsules incorporating IgG Fc-binding domain derived from Staphylococcus aureus protein A for displaying IgGs on immunosensor chips. , 2011, Biomaterials.

[39]  G. Schuler,et al.  Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. , 2010, Blood.

[40]  Gerald Striedner,et al.  Npro fusion technology to produce proteins with authentic N termini in E. coli , 2007, Nature Methods.

[41]  P. Chomez,et al.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives , 2007, Expert review of vaccines.

[42]  Bruce Stillman,et al.  Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. , 2007, Cancer cell.

[43]  R. Steinman,et al.  Differential Antigen Processing by Dendritic Cell Subsets in Vivo , 2007, Science.

[44]  Michel C Nussenzweig,et al.  Stable T cell–dendritic cell interactions precede the development of both tolerance and immunity in vivo , 2005, Nature Immunology.

[45]  Harold A Scheraga,et al.  Atomically detailed folding simulation of the B domain of staphylococcal protein A from random structures , 2003, Proceedings of the National Academy of Sciences of the United States of America.